Creatine kinase (EC 2.7.3.2) B-subunit activity in serum may be routinely measured as residual activity after specit ic immunoinhibition of the M-subunit. We assessed the inhibition kinetics, specificity, completeness of inhibition, and inhibitory capacity of three different anti-M preparations, with use of isolated human BB, MM, and MB isoenzymes. The Scandinavian-recommended reaction system was used. We suggest a set of tentative quality requirements for anti-M for use in diagnosing acute myocardial infarction. The need to measure and subtract sample residual adenylate kinase activity was demonstrated.
. After immunoinhibition by anti-M, CK B-subunit dependent activity may be determined as the residual CK activity. 3 We demonstrate in this report that the method is specific for CK B activity if assay conditions are appropriate. Theoretically, after such inhibition, in a mixture of all three CK dimers, all of CK isoenzyme BB and half of CK MB will be measured. However, the fraction B measured in the MB hybrid may vary among different batches of anti-M.
The method cannot discriminate between CK BB and CK MB. Consequently, results of such measurements in serum are most correctly expressed as S-CK B activity (4-6), and should not be multiplied by the theoretical factor of two, to be expressed as CK MB activity.
We have previously described a routine S-CK B method at 37 #{176}C based on the jointly developed Scandinavian (37 #{176}C) (7, 8) and German (25 #{176}C) (9) recommended CK methods, and clinical evaluations of the method as applied to the diagnosis of acute myocardial infarction (5, 10, 11) . (S-). Received Feb. 15, 1979 ; accepted May 7, 1979. After the conclusion of these studies, information on the effect of such chelators as ethylenediaminetetraacetate on CK reaction rates (12, 13) and on CK reagent stability (14, 15) necessitated a revision of the Scandinavian CK method (8, 16) and a re-investigation of anti-M in the presence of ethylenediaminetetraacetate.
Departments of Clinical
The manufacturer kindly put several experimental preparations of anti-M at our disposal for investigation. The following is a detailed study of the properties of anti-M immunoinhibitors in the revised Scandinavian CK reaction system, a survey of different modes of clinical application of the method, and a summary of clinical results obtained during the last three years.
Materials
The CK reaction medium ( 
Quality Controls
Preparations of CK isoenzymes MM, MB, and BB were diluted to suitable activity in a modification of the medium described by Rosalki (17) . In a mixture consisting of Tris-HC1
buffer (50 mmol/L, pH 7.00, 25 #{176}C), fl-mercaptoethanol (50 mmol/L), glycerol (5 mol/L), bovine y-globulin (Sigma, 10 g/L), and ethylenediaminetetraacetate, 3 mmol/L, dispensed in 2-mL portions into small vials and stored at -70 #{176}C, the CK MM and BB preparations showed no loss and CK MB only a slight decrease in activity during four months. Additionally, we used a control serum, "Precipath E" (Boehringer). As daily quality controls we used Precipath E and CK BB, MB, and MM, for control of the total CK and CK B determinations. In addition, every tenth sample in all series was a Precipath E. Data on imprecision are given in Results.
Measuring Techniques

Photometry.
For all routine measurements except determination of the reference range for S-CK B we used an LKB model 8600 or 2086 photometric reaction-rate analyzer with the temperature set at 37 #{176}C. We incubated 50 L of sample in LKB cuvets with 1000 1zLof CK reagent (without creatine phosphate), with and without anti-M, for a minimum of 15 mm in the thermostating tunnel of the instrument. The re- and 10 mmol of Mg2. The bioluminiscence assays were calibrated by the above-described routine photometric method. For each series, CK BB and MM controls and three patients' sera with a CK B activity of about 30 U/L, for use in calibration, were measured in both instruments.
Residual adenylate kinase activity was first monitored for 60 s in the absence of creatine phosphate (22) . 
Results
Time Course of Immunoinhibition
We studied the kinetics of immunoinhibition at 37 #{176}C with different preparations of anti-M. Racks of cuvets with 1 mL of CK reagent without creatine phosphate but with antibody included were preheated for 15 mm in the thermostating tunnel of the LKB 2086. The tunnel lid was then removed and 50-zL samples were pipetted as rapidly as possible, starting with the last cuvet. Contents of all cuvets were mixed manually with a glass rod and the reaction rates were measured at the time intervals shown on the abscissa of Figure 1 . Qualitative differences were noted between two anti-M preparations (numbers 7915327 and 14326) at a concentration of 250 mg/L in the CK reagent A. With preparation no. 14326, equilibrium of inhibition was reached within 10 mm, and inhibition of CK MM was more than 99.9% complete, with about 50% inhibition of CK MB and negligible inhibition of CK-BB.
In contrast, immunoinhibition of the isolated isoenzymes MB and MM by the experimental preparation no. 7915327 took 5. nearly three times longer to reach equilibrium. Maximal inhibition of CK MM by no. 7915327 was about 99-99.5%, but never 100% (Table 2) , with about 60% inhibition of CK MB and about 7% inhibition of CK BB. Consequently, for routine determination with preparation no. 14326, sample racks could be inserted into the LKB 2086 directly after pipetting, whereas preparation no. 7915327 required a minimum of 20 mm incubation at room temperature before the racks were placed into the instrument. Extension of incubation time with no. 7915327 beyond 20 mm did not increase inhibition of M-subunit activity. For all antibody preparations it was essential to mix the contents of all cuvets very thoroughly immediately after pipetting (we used an LKB Multimixer for a minimum of 30 s).
Omission of thorough mixing resulted in nonlinear reaction curves with decreasing reaction rates after the start with creatine phosphate. S-CK B activity was stable at 37 #{176}C for at least a further 30 mm after inhibition equilibrium had been reached. Figure 2 . The residual CK B activity determined in a freshly isolated CK MB hybrid is shown in Figure 2B .
Anti-M Concentration in CK Reagent
Correction for incomplete M-Subunit Inhibition and for Serum Adenylate Kinase Activity
With proper corrections, routine use of an anti-M that inhibits less than 99.9% of M-subunit activity is possible. For ). An example is shown in Figure  3 . S-CK B activity, uncorrected for 1% of total S-CK, showed a prolonged increase, thus indicating a continued enzyme release from the myocardium. In contrast, S-CK B, when corrected for 1% of total S-CK, rapidly returned to and remained below the discrimination limit for acute myocardial infarction ( Figure 3 ). The method can thus discriminate between S-CK B and total S-CK, even when the proportion of S-CK B fraction is as low as 0.5%.
Interference by Serum Adenylate Kinase
In the Scandinavian CK reagent, the adenylate kinase inhibitor combination AMP, 5 mmol/L, and 3,5-diadenosine-5-pentaphosphate, 10 mol/L, efficiently inhibits S-adenylate kinase from erythrocytes, thrombocytes, muscle, and liver, but not completely (7, 25, 26) . 
Imprecision of the Routine Photometry Method
Because of limitations inherent in spectrometry, imprecision increases sharply with decrease of reaction rates below 15 U/L, as illustrated in Figure 5 . This situation cannot be remedied by simply increasing the sample volume, because there is no proportionality between sample volume fraction and the corresponding reaction rates (7, 8, 16) . The within-day imprecision (CV) of a determination of S-adenylate kinase having an activity of 5 U/L is about 15%. Consequently, subtraction of these low residual S-adenylate kinase activities increases the imprecision of apparent CK B results, as shown in Figure 5 . (For details see ref. 4 .) The within-day imprecision of corrected S-CK B values at the discriminatory level of 12 U/L was about 8%, corresponding to a day-to-day imprecision of 10%. The subtraction of increased residual S-adenylate kinase activities has previously been shown to prevent falsely high S-CK B results (10, 11) . Day-to-day imprecision of total S-CK and S-CK B in daily quality controls is given in Table   3 ,
Reference Ranges of S-CK and S-CK B
Sera from patients judged to be healthy by several clinical and laboratory criteria were put at our disposal by a current reference-range project (the Kristianstad survey). 
S-CK and S-CK B Activities
Discussion
Reaction Conditions
Our routine photometric method is based on the Scandinavian CK reagent (8) and a standard reaction temperature of 37 #{176}C. Under these conditions the CK reaction follows apparent zero-order kinetics at 2000 U/L for at least 180 s (7) . At this rate NADPH concentration will reach 250 tmol/L in 180 s, corresponding to an NA1)PH/NADP ratio of 0.1, above which NADPH becomes significantly inhibitory (9) . The anti-M concentration in the reagent was adjusted to inhibit more than 2000 U of CK-MM activity per liter. CK B subunit activity was stable at 37 #{176}C in the CK-reagent for at least 30 mm after equilibrium of inhibition had been reached. Because photometric imprecision increases steeply at low reaction rates, it is an advantage to use the highest reaction temperature compatible with CK B stability. 
CK-MB Control
For establishing inhibition properties of anti-M it is essential to use a CK-MB isoenzyme freshly isolated from serum from an acute myocardial infarction patient. On storage in buffer at various temperatures ranging from 25 to -20 #{176}C, the isolated MB hybrid rapidly dissociates and forms MM and BB. In imidazole buffer, pH 6.7 at 25 #{176}C, B subunits stored at 4 or -20 #{176}C are less stable than M subunits (10), leading to a relative loss of B subunit activity. Apparently, a similar loss occurs on lyophilization, as observed in our lyophilized CK-MB control, which had only about 40% CK B activity.
Theoretically, unspecific inhibition of B-subunit activity in CK-BB and CK-MB should correlate, so that a 5% inhibition of B-subunit activity should result in a 10% inhibition of CK-BB and a 5% inhibition of B in MB. Expressed as fraction residual activity of the uninhibited activity, this would correspond to 90% BB and 45% MB activity. 3. At an anti-M concentration that inhibits CK-MM by more than 99.9% the measurable fraction of CK-B subunit activity in a freshly isolated CK-MB hybrid should be at least 45 to 50% of the total CK-MB activity. 4. At the same anti-M concentration the inhibition of CK-BB should be less than 5%.
This report demonstrates qualitative and quantitative differences among different anti-M preparations, even from the same species of animal. Consequently, new anti-M preparations for diagnostic use should be tested and their immunoinhibition properties, as described above, should be stated. Our quality criteria were fulfilled by only one anti-M preparation, no. 14326, which now is commercially available in Europe as CK MB 14326 reagent kit (E. Merck, F.R.G.).
Analytical Specificity
Two factors primarily determine the analytical specificity for CK B: (a)residual M-subunit activity left by incomplete immunoinhibition, and (b) residual sample adenylate kinase activity. It is possible routinely to correct for both to prevent false-positive results.
Two of the three anti-M preparations tested left a residual M-subunit activity of 0.5-1%. In a serum sample with, e.g., 2000 U of CK MM activity per liter such an immunoinhibitor will give a residual M-subunit activity of 10-20 UIL, depending on the anti-M preparation and the photometric imprecision at this level of activity ( Figure 5 ). This activity will exceed the discrimination limit for S-SK B (5, 10, 11, 23, 24) in acute myocardial infarction in some cases. We have previously documented that subtracting an arbitrary 1% of total S-CK from the apparent S-CK B activity (after correction for residual 5-adenylate kinase activity) reduced the frequency of false-positive results from 4% to 1% in 303 patients without myocardial infarction (5, 11) .
Residual sample adenylate kinase activity depends on the efficiency of the adenylate kinase inhibitors used in the reagent. The efficiency of the combined AMP and diadenosine-5-pentaphosphate used in the jointly recommended Scandinavian and German CK reagents has been extensively investigated (7, 9, 25, 26) . No inhibitor combination known to us, including AMP and fluoride (27, 28) , inhibits adenylate kinase completely without a concurrent unacceptable inhibition of CK. From Figure 4 it can be estimated that the probability for a sample residual adenylate kinase activity of at least 9 U/L is about 0.1. The probability for a normal S-CK B of at least 3 U/L is 0.5. Consequently, it may be estimated that the probability for the combination of a residual adenylate kinase activity of at least 9 U/L plus a S-CK B of at least 3 U/L will lead to a falsely positive apparent S-CK B in at least 5% of the samples. In a previous study with the relatively high discrimination limit of 15 UIL, subtracting sample adenylate kinase prevented 8% false-positive results in 1117 samples from 303 patients without myocardial infarction (11) .
With an average sampling frequency of four samples per patient this procedure prevented 20% of these patients from having a false diagnosis of myocardial infarction. The diagnostic utility of anti-M no. 1976, used with both of the above-mentioned corrections, has been extensively reported in ref.
11.
Serum CK B in Acute Myocardial infarction For use in the diagnosis of acute myocardial infarction S-CK B determination may be utilized in at least three modes:
1. using a relative discrimination limit, expressing S-CK B as a fraction of total S-CK 2. relating to a S-CK B discriminating threshold expressed in U/L
requiring minimal changes of S-CK B during a certain interval
The use of a relative discrimination limit of 3% S-CK B-i.e., 6% expressed as S-CK MB-was initiated in Germany (2, 29) in order to avoid false-positive results owing to extracardial S-CK MB activity. In our opinion, this procedure suffers from the following disadvantages:
1. As with any ratio, it comprises the analytical imprecision of two separate assays. 2. False negatives can occur with samples from cases of acute myocardial infarction that have high total S-CK activity, owing to extracardial CK MM-e.g., as a consequence of intramuscular injections (11, 30) . 3. The S-CK B/S-CK ratio does not convey the information required for the clinician to monitor the course of the infarction (Figure 8 ) or calculate the amount of CK B released (30, 31) . For instance, the fractions S-CK B calculated in Figure 8 are similar at peak S-CK B and for the 42-h sample. As is evident from the reference values, the fraction S-CK B of total S-CK actually exceeds 3% in many healthy persons with low total CK activity.
Extracardial S-CK MB has been reported in cases of Duchenne muscular dystrophy (32, 33) , and in some other conditions such as shock, polytrauma, acute psychosis, and severe alcohol intoxication (34) . In recent reports on extracardial conditions (29, 34) determinations of CK-MB were made with a reagent containing only AMP as the adenylate kinase inhibitor. It was not stated whether corrections were made for residual 5-adenylate kinase activity or correction for incomplete immunoinhibition, or both. Most of these conditions do not pose any differential diagnostic problems with respect to acute myocardial infarction. For surveys see refs. 11,35, and 36. During three years of routine S-CK B determinations on more than 1000 patients suspected of having had a myocardial infarction we have observed only one case of extracardial CK MB (23) . Additionally, CK isoenzyme electrophoreses on more than 300 patients without myocardial infarction failed to demonstrate increased CK MB activity in more than 1%. However, we did find CK isoenzyme BB in five cases of cardiac arrest, probably a result of leakage from hypoxic brain tissue.
Also, a variant CK BB isoenzyme with abnormal electrophoretic mobility was demonstrated at a frequency of about 1% of all cases ( Figure 7, ref 6) .
The second mode is to use a fixed discrimination value for S-CK B. Ljungdahl (11) used a discrimination limit of 15 UIL in a retrospective study from a coronary-care unit, based on 6-h sampling intervals and peak enzyme values in each patient. In 227 classifiable patients with a prevalence of infarction of 0.47, he found a diagnostic sensitivity of 0.98 and a diagnostic specificity of 0.99. Also using an immunoinhibition method, Werner and Mohrbacher were used. Diagnostic sensitivity and specificity were 0.99 and 1.00, respectively. Based on the first positive S-CK B value in each patient, the predictive value for a positive result (PV) was 1.00. Based on all negative values in the 10-to 20-h interval after onset of acute symptoms the PVneg was 0.99. These results correlate very well with an evaluation of S-CK MB after column chromatography of samples collected during three consecutive days after onset of symptoms in a prospective study of 201 patients suspected of having had an acute myocardial infarction, with acute myocardial infarction prevalence of 0.5, giving diagnostic sensitivity and specificity of 0.98 and 0.97, respectively (38) .
The third mode is to monitor changes of S-CK B activity in serial samples taken within a relatively short time interval after admission to the hospital. 
